Several drugs targeting nodes of the two pathways have been developed, and three representative agents (PI3k/mTOR dual inhibitor BEZ235, mTORC1 inhibitor everolimus, and MEK inhibitor AZD6244) FDA-approved for the treatment of various cancers were used in our work. Here, MAP2K7 is linked to cancer.